Genfit shares give up 0.5% but keep a 32% gain over one month

A slight pullback that does not call into question the rebound begun at the end of October

The stock gives up 0.73% to €10.94, while the SBF 120 gains 1.12%, placing it near the bottom of the index for the session. It nevertheless retains a 32% gain over one month, in contrast with a decline of nearly 20% over three months.

The share price remains above its 20-day moving average (MM20), with a gap of 10.39%, and the RSI at 56 is neutral.

Genfit is approaching its resistance at €11.46, a level the stock had broken above in early November, before its accounts were published.

Royalties received on Iqirvo rose 188% over nine months, to €36.3 million, according to the publication of November 5, while total revenue fell to €36.4 million. The company also indicated that these items allow it to finance its activities beyond the end of 2028.

Nangibotide in ACLF: first Phase 2a data expected in 2027

On November 8, in Denver, at the AASLD congress, Genfit detailed Nangibotide in acute decompensation of cirrhosis, its main drug candidate. The efficacy signals put forward come from studies conducted in septic shock and severe COVID-19, not in ACLF itself. The first Phase 2a results in this indication are expected in 2027.

On the diagnostics front, Medicare approved reimbursement for the NASHnext test in August, a market the company estimates at more than $1.5 billion by 2033. The next level to watch on the stock remains the resistance at €11.46.